Literature DB >> 32277426

MiR-206 suppresses proliferation and epithelial-mesenchymal transition of renal cell carcinoma by inhibiting CDK6 expression.

Zhen Guo1, Haiyan Jia2, Junke Ge3.   

Abstract

Increasing evidence indicates that miRNAs are involved in tumorigenesis of human renal cell carcinoma (RCC). However, the role of miR-206 is still unknown. This study aimed to investigate the possible mechanism of miR-206 in progression of RCC. Here, compared with adjacent normal renal tissues and HK-2 cells, miR-206 level was markedly decreased, whereas CDK6 level was obviously increased in RCC tissues and cell lines. MiR-206 was inversely associated with lymph node metastasis and TNM stage, and acted as an independent prognostic factor in RCC. MiR-206 effectively caused apoptosis and cell cycle arrest at G0/G1 phase, and affected the growth of xenograft tumor of nude mice. MiR-206 also inhibited migration and invasion of RCC cells by modulating the expressions of EMT-related genes. Dual-luciferase assay demonstrated CDK6 was a direct target of miR-206. CDK6 silencing aggravated the inhibition effects of miR-206. In conclusion, miR-206 suppresses proliferation and EMT of RCC by inhibiting CDK6 expression. The miR-206/CDK6 axis may provide a novel insight into tumorigenesis of RCC.

Entities:  

Keywords:  CDK6; MiR-206; RCC; Suppression

Mesh:

Substances:

Year:  2020        PMID: 32277426     DOI: 10.1007/s13577-020-00355-5

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  19 in total

1.  Notch-mediated repression of bantam miRNA contributes to boundary formation in the Drosophila wing.

Authors:  Isabelle Becam; Neus Rafel; Xin Hong; Stephen M Cohen; Marco Milán
Journal:  Development       Date:  2011-07-27       Impact factor: 6.868

2.  Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal Cell Carcinoma Outpatients Treated with Pazopanib.

Authors:  Maki Todo; Suguru Shirotake; Koshiro Nishimoto; Yota Yasumizu; Gou Kaneko; Hideyuki Kondo; Takashi Okabe; Hideki Makabe; Masafumi Oyama
Journal:  Anticancer Res       Date:  2019-02       Impact factor: 2.480

3.  Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT.

Authors:  Alexa R Meyer; Michael A Carducci; Samuel R Denmeade; Mark C Markowski; Martin G Pomper; Philip M Pierorazio; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Ann Nucl Med       Date:  2019-05-30       Impact factor: 2.668

4.  MicroRNA-206 Inhibited the Progression of Glioblastoma Through BCL-2.

Authors:  Wenjiong Hao; Wei Luo; Mangmang Bai; Jian Li; Xiaobin Bai; Jie Guo; Jinsong Wu; Maode Wang
Journal:  J Mol Neurosci       Date:  2016-08-25       Impact factor: 3.444

Review 5.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Authors:  Rajesha Rupaimoole; Frank J Slack
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

Review 6.  MicroRNAome genome: a treasure for cancer diagnosis and therapy.

Authors:  Ioana Berindan-Neagoe; Paloma del C Monroig; Barbara Pasculli; George A Calin
Journal:  CA Cancer J Clin       Date:  2014-08-07       Impact factor: 508.702

Review 7.  MicroRNAs: target recognition and regulatory functions.

Authors:  David P Bartel
Journal:  Cell       Date:  2009-01-23       Impact factor: 41.582

8.  The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Authors:  Hiten D Patel; Maneka Puligandla; Brian M Shuch; Bradley C Leibovich; Anil Kapoor; Viraj A Master; Charles G Drake; Daniel Yc Heng; Primo N Lara; Toni K Choueiri; Deborah Maskens; Eric A Singer; Scott E Eggener; Robert S Svatek; Walter M Stadler; Suzanne Cole; Sabina Signoretti; Rajan T Gupta; Marc Dror Michaelson; David F McDermott; David Cella; Lynne I Wagner; Naomi B Haas; Michael A Carducci; Lauren C Harshman; Mohamad E Allaf
Journal:  Future Oncol       Date:  2019-04-10       Impact factor: 3.404

9.  Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.

Authors:  Tadashi Tabei; Noboru Nakaigawa; Tomohiro Kaneta; Ichiro Ikeda; Keiichi Kondo; Kazuhide Makiyama; Hisashi Hasumi; Narihiko Hayashi; Takashi Kawahara; Koji Izumi; Kimito Osaka; Kentaro Muraoka; Jun-Ichi Teranishi; Yasuhide Miyoshi; Yasushi Yumura; Hiroji Uemura; Kazuki Kobayashi; Tomio Inoue; Masahiro Yao
Journal:  BMC Cancer       Date:  2019-04-02       Impact factor: 4.430

10.  miR-206 Inhibits Cell Proliferation, Migration, and Invasion by Targeting BAG3 in Human Cervical Cancer.

Authors:  Yingying Wang; Yongjie Tian
Journal:  Oncol Res       Date:  2018-01-02       Impact factor: 5.574

View more
  4 in total

Review 1.  MicroRNA Signature in Renal Cell Carcinoma.

Authors:  Soudeh Ghafouri-Fard; Zeinab Shirvani-Farsani; Wojciech Branicki; Mohammad Taheri
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

2.  miR-206 Inhibits Laryngeal Carcinoma Cell Multiplication, Migration, and Invasion.

Authors:  Yiling Liu; YunTao Song; Xiaojuan Chen; Junfang Fan; Wei Zheng; Chen Cao
Journal:  J Healthc Eng       Date:  2021-11-26       Impact factor: 2.682

3.  Application of Bidirectional Generative Adversarial Networks to Predict Potential miRNAs Associated With Diseases.

Authors:  Long Xu; Xiaokun Li; Qiang Yang; Long Tan; Qingyuan Liu; Yong Liu
Journal:  Front Genet       Date:  2022-07-12       Impact factor: 4.772

Review 4.  Prognostic Value and Clinicopathological Features of MicroRNA-206 in Various Cancers: A Meta-Analysis.

Authors:  Rongqiang Liu; Shiyang Zheng; Shengjia Peng; Yajie Yu; Jianwen Fang; Siwen Tan; Fan Yao; Zhihua Guo; Yi Shao
Journal:  Biomed Res Int       Date:  2020-10-20       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.